One type of androgen deprivation therapy may speed coronary plaque growth in men being treated for localized prostate cancer.
Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...
ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?
The REVELUTION (Relugolix versus Leuprolide Cardiac) trial compared coronary plaque after 2 types of androgen deprivation therapy (ADT) for prostate cancer.
The phase 2b study is an open-label trial that will enroll 40 men with advanced prostate cancer who are appropriate candidates for ADT. Participants will receive an initial loading dose of teverelix ...
Bayer's Nubeqa gains approval in India for non-chemotherapy treatment of advanced prostate cancer, enhancing patient care ...
When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...